Shield Therapeutics (LSE:STX) Treasury Stock : £0.00 Mil (As of Jun. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Shield Therapeutics Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Shield Therapeutics's treasury stock for the quarter that ended in Jun. 2023 was £0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Shield Therapeutics Treasury Stock Historical Data

The historical data trend for Shield Therapeutics's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shield Therapeutics Treasury Stock Chart

Shield Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Treasury Stock

Get a 7-Day Free Trial

Shield Therapeutics Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Treasury Stock	Get a 7-Day Free Trial													-	-	-	-	-

Shield Therapeutics Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Shield Therapeutics (LSE:STX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (LSE:STX) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

SHIEF:USA 1JS:Germany

Address

Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF

Website

https://www.shieldtherapeutics.com

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments are based on key products including Accrufer/Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available, and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from Feraccru segment.